MiR-342-5p inhibits osteosarcoma cell growth, migration, invasion, and sensitivity to Doxorubicin through targeting Wnt7b. Issue 23 (2nd December 2019)

• Record Type: Journal Article
• Authors: Liu, Qing; Wang, Zhenting; Zhou, Xiaohua; Tang, Mingying; Tan, Wei; Sun, Tianshi; Deng, Youwen
• Is Part Of: Cell cycle. Volume 18:Issue 23(2019)
• Page Start: 3325
• Page End: 3336
• Publication Date: 2019-12-02
• Subjects: Osteosarcoma (OS) -- Wnt/β-catenin signaling -- miR-342-5p -- Wnt7b; Cell cycle -- Periodicals; 571.84377
• DOI: 10.1080/15384101.2019.1676087
• Languages: English
• ISSNs: 1538-4101

Abstract

ABSTRACT: Osteosarcoma (OS) accounts for 9 percent of cancer-related deaths in young people. The PI3K/Akt signaling, a well-known carcinogenic signaling pathway in human cancer, cooperates with other signaling pathways such as Wnt signaling to promote cancer progression. Wnt7b, as a transforming member of the Wnt family, could activate mTORC1 through PI3K-AKT signaling and is upregulated in OS. In the present study, we found that miR-342-5p inhibits Wnt7b expression via direct binding to Wnt7b 3′-UTR. miR-342-5p overexpression remarkably suppressed the viability and invasion while enhanced the apoptosis of OS cells; meanwhile, Wnt7b, β-catenin, c-myc, and cyclin D1 proteins were reduced while E-cadherin protein showed to be increased. Consistent with its expression pattern, Wnt7b exerted oncogenic effects on OS cells. Wnt7b could significantly attenuate the impacts of miR-342-5p. In conclusion, we demonstrated a miR-342-5p/Wnt7b axis that regulates the capacity of OS cells to proliferate and to invade through Wnt/β-catenin signaling. The miR-342-5p/Wnt7b axis might be novel targets for OS targeted therapy, which needs further in vivo and clinical investigations.